reported that 11/12 (91.7%) LCC had TP53 mutations and 1/12 (8.3%) an activating mutation in MET, while none had KRAS or RB1 alterations [4]. The gene discussed is KRAS; the disease is leukoencephalopathy with calcifications and cysts.